Zydus Lifesciences Ltd Analyst Rating
based on 33 analysts
46.88%
Buy
31.25%
Hold
21.88%
Sell
Based on 33 analysts offering long term price targets for Zydus Lifesciences Ltd. An average target of ₹1083.36
Source: S&P Global Market Intelligence
Zydus Lifesciences Ltd Share analysis
Zydus Lifesciences Ltd price forecast by 33 analysts
Upside of9.92%
High
₹1380
Target
₹1083.36
Low
₹794
Zydus Lifesciences Ltd target price ₹1083.36, a slight upside of 9.92% compared to current price of ₹973.5. According to 33 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Zydus Lifesciences Ltd revenue growth forecast
Expected growth rate Q1, FY2026:24.31%
Forecast
Actual
Including amortisation and stock based compensations
Zydus Lifesciences Ltd EPS growth forecast
EPS estimate Q1, FY2026:20.13%
Forecast
Actual
Source: S&P Global Market Intelligence
Zydus Lifesciences Ltd Performance
Day's Low
Day's High
₹970.3Day's Price Range₹990.9552 Week's Low
52 Week's High
₹648.1552-Week Price Range₹1,324.3
| Returns % | |
| 1 Month Return | + 4.4 % |
| 3 Month Return | -6.6 % |
| 1 Year Return | + 46.79 % |
| Market Stats | |
| Previous Close | ₹985.60 |
| Open | ₹990.10 |
| Volume | 9.11L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹98,565.65Cr |
Zydus Lifesciences Ltd Key Statistics
| P/E Ratio | 23.1 |
| PEG Ratio | 1.55 |
| Market Cap | ₹98,565.65 Cr |
| P/B Ratio | 6.43 |
| EPS | 38.31 |
| Dividend Yield | 0.3 |
| Sector | Pharmaceuticals |
| ROE | 23.45 |
Zydus Lifesciences Ltd Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| HOLD | ₹98,565.65 Cr | 55.28% | 0.64 | ₹3,854 Cr | ₹19,547 Cr | |
| BUY | ₹14,100.35 Cr | -2.24% | 0.52 | ₹602 Cr | ₹2,851 Cr | |
| BUY | ₹73,098.77 Cr | 33.6% | 0.56 | ₹3,168 Cr | ₹29,001 Cr | |
| BUY | ₹59,732.90 Cr | 24.06% | 0.53 | NA | NA | |
| BUY | ₹39,514.80 Cr | 8.34% | 0.56 | ₹589 Cr | ₹3,453 Cr |
About Zydus Lifesciences Ltd
The company has a strong presence in the global market and is known for its high-quality pharmaceutical products. It manufactures a wide range of generic and specialty drugs, including cardiovascular, anti-infective, anti-diabetic, and oncology medicines. Zydus also produces over-the-counter products and nutritional supplements. Some of its top products include Zetia, Atorvastatin, and Metformin.
Zydus Lifesciences Ltd is also known for its popular brands, such as Cadila, Nutralite, and Zydus Wellness. The company has a strong presence in the Indian market, with its products being sold in more than 20,000 stores across the country. It also exports its products to over 100 countries worldwide.
Share Price: ₹973.50 per share as on 20 Dec, 2024 04:01 PM
Market Capitalisation: ₹98,565.65Cr as of today
Revenue: ₹5,113.60Cr as on September 2024 (Q3 24)
Net Profit: ₹898.10Cr as on September 2024 (Q3 24)
Listing date: 18 Apr, 2000
Chairperson Name: Pankaj R Patel
| Organisation | Zydus Lifesciences Ltd |
| Headquarters | Ahmedabad |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Zydus Lifesciences Ltd
Zydus Secures USFDA Approval for Anesthetic Cream - 19 Dec, 2024
Zydus Lifesciences has received USFDA approval for Lidocaine and Prilocaine Cream, a topical anesthetic, with annual sales of $22.05 million in the US market. This marks the company's 412th approval, reflecting its strong presence in the US generic drug market.Zydus Lifesciences Faces GST Demand Amid Strong Financials - 29 Nov, 2024
Zydus Lifesciences received a Rs 1.61 crore GST demand for FY 2017-18 related to Input Tax Credit. The company plans to appeal, stating no material financial impact. Meanwhile, its Q2 FY25 net profit rose 13.8% to Rs 911.20 crore, with a 20.1% revenue increase. The stock rose 2% to Rs 967.35.Zydus Group's IMKELDI Receives USFDA Approval - 27 Nov, 2024
Shilpa Medicare, in collaboration with Zydus Group's Oncosol and Shorla Oncology, announced USFDA approval for IMKELDI, the first oral liquid form of imatinib for cancer treatment.
Insights on Zydus Lifesciences Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTFII Holding Up
Foreign Institutions have increased holdings from 5.59% to 7.52% in Sep 2024 quarter
- POSITIVE IMPACT
Retail Holding Up
Retail Investor have increased holdings from 6.80% to 6.85% in Sep 2024 quarter
NO EFFECTAgainst Peers
In the last 1 year, Divis Laboratories Ltd has given 57.1% return, outperforming this stock by 14.3%
- NO EFFECT
Against Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 135.8% return, outperforming this stock by 15.7%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 74.98% of holdings in Sep 2024 quarter
NEGATIVE IMPACTRevenue Fall
Revenue is down for the last 2 quarters, 6.27K Cr → 5.30K Cr (in ₹), with an average decrease of 15.4% per quarter
- NEGATIVE IMPACT
Price Dip
In the last 6 months, ZYDUSLIFE stock has moved down by -8.8%
- NEGATIVE IMPACT
MF Holding Down
Mutual Funds have decreased holdings from 7.24% to 6.57% in Sep 2024 quarter
- NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, 1.41K Cr → 911.2 Cr (in ₹), with an average decrease of 35.8% per quarter
Zydus Lifesciences Ltd Financials
Index Inclusions
Zydus Lifesciences Ltd Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 74.98% | 0.00 | |
| Foreign Institutions | 7.52% | 34.61 | |
| Mutual Funds | 6.57% | ||
| Retail Investors | 6.85% | 0.71 | |
| Others | 4.08% |
Zydus Lifesciences Ltd Key Indicators
Zydus Lifesciences Ltd Valuation
Zydus Lifesciences Ltd in the last 5 years
Lowest (7.34x)
March 7, 2022
Today (23.10x)
December 19, 2024
Industry (56.23x)
December 19, 2024
Highest (34.62x)
March 26, 2024
Zydus Lifesciences Ltd Earnings and Dividends
Zydus Lifesciences Ltd Earnings Results
Zydus Lifesciences Ltd’s net profit jumped 13.8% since last year same period to ₹911.20Cr in the Q2 2024-2025. On a quarterly growth basis, Zydus Lifesciences Ltd has generated -35.83% fall in its net profits since last 3-months.
Read More about Earnings ResultsZydus Lifesciences Ltd Dividends May,2024
In the quarter ending March 2024, Zydus Lifesciences Ltd has declared dividend of ₹3 - translating a dividend yield of 0.92%.
Read More about Dividends
Zydus Lifesciences Ltd Technicals Summary
Bearish
Neutral
Bullish
Zydus Lifesciences Ltd is currently in a Bearish trading position according to technical analysis indicators.
FAQs on Zydus Lifesciences Ltd
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Zydus Lifesciences Ltd shares.
Zydus Lifesciences Ltd (ZYDUSLIFE) share price today is ₹973.5
Zydus Lifesciences Ltd is listed on NSE
Zydus Lifesciences Ltd is listed on BSE
- Today’s highest price of Zydus Lifesciences Ltd is ₹990.95.
- Today’s lowest price of Zydus Lifesciences Ltd is ₹970.3.
PE Ratio of Zydus Lifesciences Ltd is 23.1
PE ratio = Zydus Lifesciences Ltd Market price per share / Zydus Lifesciences Ltd Earnings per share
Today’s traded volume of Zydus Lifesciences Ltd(ZYDUSLIFE) is 9.11L.
Today’s market capitalisation of Zydus Lifesciences Ltd(ZYDUSLIFE) is ₹98565.65Cr.
| Zydus Lifesciences Ltd(ZYDUSLIFE | Price |
|---|---|
52 Week High | ₹1324.3 |
52 Week Low | ₹648.15 |
Zydus Lifesciences Ltd(ZYDUSLIFE) share price is ₹973.5. It is down -26.49% from its 52 Week High price of ₹1324.3
Zydus Lifesciences Ltd(ZYDUSLIFE) share price is ₹973.5. It is up 50.20% from its 52 Week Low price of ₹648.15
| Zydus Lifesciences Ltd(ZYDUSLIFE | Returns |
|---|---|
1 Day Returns | -12.1% |
1 Month Returns | 4.4% |
3 Month Returns | -6.6% |
1 Year Returns | 46.79% |